Trial Profile
A Multicenter Study to Compare the Efficacy of a Prophylactic Use of Tenofovir by Duration for the Non-Hodgkin's Lymphoma Patients With Isolated Anti-HBc-positivity Who Will be Treated With Rituximab Based Chemotherapy
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 23 Jul 2023
Price :
$35
*
At a glance
- Drugs Tenofovir disoproxil fumarate (Primary)
- Indications Hepatitis B
- Focus Therapeutic Use
- 17 Jul 2023 Status changed to completed, according to Results published in the Journal of Korean Medical Science
- 17 Jul 2023 Primary endpoint has not been met (HBV reactivation: defined as an increase in HBV DNA at least 10 folds from nadir or reappearance of HBsA or HBeAg in blood during treatment) , according to Results published in the Journal of Korean Medical Science
- 17 Jul 2023 Results published in the Journal of Korean Medical Science